Institutional members access full text with Ovid®

Share this article on:

Safety and Tolerability of High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis

Hand, Elizabeth O. PharmD, BCPS*†‡; Ramanathan, Meenakshi R. PharmD*†§

The Pediatric Infectious Disease Journal: August 2014 - Volume 33 - Issue 8 - p 835–836
doi: 10.1097/INF.0000000000000335
Antimicrobial Reports

Children with hematologic malignancies are at an increased risk of invasive fungal infections and a greater risk has been seen with exposure to building construction. Prophylaxis with high-dose (IV) liposomal amphotericin B (L-AmB) 10 mg/kg once weekly was initiated in our high risk children based on previous pharmacokinetic studies. This treatment regimen was associated with a 26% incidence of adverse infusion reactions.

From the *Pharmacotherapy Division, The University of Texas at Austin College of Pharmacy, Austin; Pharmacotherapy Education and Research Center, Department of Medicine, The University of Texas Health Science Center at San Antonio; University Hospital; and §Pharmacy Department, The Children’s Hospital of San Antonio, San Antonio, TX.

Accepted for publication March 5, 2014.

The authors have no funding or conflicts of interest to disclose.

Address for correspondence: Elizabeth O. Hand, PharmD, BCPS, 7703 Floyd Curl Drive, PERC, MC 6220, San Antonio, TX 78229.

© 2014 by Lippincott Williams & Wilkins, Inc.